<?xml version="1.0" encoding="UTF-8"?>
<p>Participants will be informed about the study by their own rheumatologist. Individuals interested in participating will be asked for consent to share their contact details with the coordinating investigator. The coordinating investigator will contact the patient and provide verbal and written information, including the patient letter and informed consent form. These materials have been approved by the Dutch Central Committee on Research concerning Human Subjects. Participants do not have to respond within a set timeÂ frame, but at least 2 weeks ahead of the intended treatment date to allow time for preparation of the treatment.</p>
